New pneumonia vaccine trial aims to shield 3,000 kids from deadly infection

NCT ID NCT06617715

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Sinovac Life Sciences Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial is testing a new 13-valent pneumococcal conjugate vaccine (PCV13) in over 3,000 healthy infants and children aged 6 weeks to 5 years. The goal is to see if the vaccine is safe and triggers a strong immune response compared to an existing vaccine. If it works, it could help prevent serious diseases like pneumonia and meningitis in young children.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 13-valent pneumococcal conjugate vaccine (PCV13)
What this could lead to: If successful, this could provide a new option to protect infants and children from serious pneumococcal infections like pneumonia and meningitis.
What could go wrong: This is a large Phase 3 trial, but the vaccine may not prove as effective or safe as existing ones. Results are still pending.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIOUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PNEUMOCOCCAL INFECTIOUS DISEASE

Contacts and locations

Locations

Henan Provincial Center for Disease Control and Prevention
RECRUITING

Zhengzhou, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.